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Objective: To assess the relationship of lipoprotein(a) to early vein graft occlusions
in patients after coronary artery bypass grafting.
Methods: We studied 102 male patients (mean age 52.3 8.6 years) with chest pain
occurrence during the first year (mean time 5.3  3.0 months) after surgical
myocardial revascularization. Graft patency was examined by electron-beam com-
puted tomography (n  102) and quantitative coronary angiography (n  31).
Results: Patients were divided into 2 groups according to graft patency data: 66
(65%) with occlusions and 36 (35%) without occlusions at follow-up. No significant
differences were found between the groups concerning age, smoking, family history
of coronary heart disease, previous myocardial infarction, hypertension, serum
lipids, and apolipoprotein B. Lipoprotein(a) level was significantly higher in patients
with occluded grafts with a median (95% confidence intervals) of 24 mg/dL (17-42
mg/dL) versus 12 mg/dL (6-24 mg/dL) in patients with patent grafts, P .01. More
patients with nonoccluded grafts were taking statins postoperatively: 42% versus
18% of patients with occluded grafts, P  .05. The sensitivity and specificity of
electron-beam computed tomography in revealing vein graft occlusion was close to
100%.
Conclusion: There is an association between high lipoprotein(a) level and vein graft
occlusions in middle-aged men during the first year after coronary artery bypass
grafting. Use of statins is associated with a lower rate of vein graft occlusion.
Electron-beam tomography could be useful for assessing graft occlusions.
Coronary artery bypass grafting (CABG) is a key intervention in thetreatment of severe symptomatic coronary heart disease (CHD).Serial angiographic studies reveal that 15% to 30% of vein graftsbecome stenosed within 1 year of surgery and nearly half of themare closed at 10 years.1 Early (within the first month after CABG)graft failure is generally caused by thrombosis,2 whereas intimal
hyperplasia is the dominating process between 1 month and 1 year after implanta-
tion.3 Beyond 1 year after operation, atherosclerosis of vein grafts can develop.3
Lipoprotein(a) (Lp[a]) is an emerging cardiovascular risk factor. Most prospec-
tive studies have demonstrated up to a twofold risk of coronary events in healthy
subjects with high Lp(a) levels.4 Lp(a) is a macromolecular complex of a low-
density lipoprotein–like (LDL-like) particle and a unique glycoprotein, apolipopro-
tein(a) (apo[a]). The apo(a) molecule possesses high primary structure homology to
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the plasminogen molecule.5 It was shown that Lp(a) can
inhibit fibrinolysis6 and accumulates in atherosclerotic
plaques of both native coronary arteries7 and vein grafts.8
Studies investigating the relationship between vein graft
lesions and Lp(a) have reported conflicting results; some
have seen a correlation with late-term patency9,10 but others
failed to find a correlation with 1-year patency11 or 5-year
patency12 after operation. Given the risk of invasive angiog-
raphy,12 noninvasive assessment of vein graft patency is
desirable. Previously, it was shown that cardiac electron-
beam computed tomography (EBCT) had close to 100%
sensitivity and specificity in detection of vein graft paten-
cy.13 The aim of our study was to evaluate the association of
Lp(a) as well as lipid levels and traditional risk factors with
the first-year occlusions of vein grafts assessed by EBCT.
Patients and Methods
We studied 102 male patients (from 28 to 68 years old, mean 52.3
 8.6 years) with chest pain appearance between the first and the
twelfth month after myocardial revascularization by CABG (mean
time after operation 5.3  3.0 months). The study exclusion
criteria were secondary dyslipidemia due to diabetes mellitus,
dysfunction of thyroid gland, and liver or kidney failure.
The initial preoperative examination of all patients included
medical history, routine clinical tests (electrocardiography [ECG],
echocardiography), and coronary angiography. Before surgery,
blood samples were collected from all patients and concentrations
of total cholesterol, triglycerides, and high-density lipoprotein
cholesterol (HDL-C) were tested immediately by specific enzy-
matic techniques of Boehringer Mannheim (Mannheim, Germany)
on a Technicon RA-XT analyzer (GMI, Inc, Albertville, Minn).
Concentration of apolipoprotein B (apoB) was measured by a
turbodimetric method with monospecific polyclonal antibodies of
a goat to human LDL. LDL cholesterol (LDL-C) was calculated by
the Friedewald formula14 and, after adjustment for Lp(a)-choles-
terol contribution, according to G. Dahlen.15 Lp(a) concentration
was determined by enzyme-linked immunosorbent assay (ELISA)
using monospecific polyclonal sheep anti-human-apo(a) antibod-
ies, as described previously.16 The intra-assay coefficient of vari-
ance has been determined to be 4.3% and 3.3% at 52 and 100
mg/dL, respectively, and the interassay coefficient of variance was
9.3% and 7.8%, respectively. Cross-reactivity with LDL and plas-
minogen was negligible. Regression analysis obtained 95% corre-
lation in Lp(a) determination between our version of ELISA and a
commercial kit (TintElisa Lp[a] Biopool International, Umea,
Sweden).
For comparison of lipid parameters, we used a control group
consisting of 76 healthy male donors without a personal history of
cardiovascular disease.
Postoperatively, 100 (98%) patients received aspirin and 27
(26.5%) patients took hypolipidemic therapy by statins (simvasta-
tin, n 17; lovastatin, n 5; fluvastatin, n 5). At follow-up, all
studied patients had chest pain; bicycle ergometry was performed
in 100 of them. Although the exercise test results were positive in
only 33 patients, all were subjected to graft examination, which
was performed by EBCT with Imatron C-150 (GE Imatron, San
Francisco, Calif). Each section was made during a 0.1-second
interval with a breath-hold and with ECG gating to minimize
motion artifacts. The circulation time was determined with 120 mL
of nonionic radiopaque preparation Omnipaque 350 (Amersham
Corp, Arlington Heights, Ill) given by an automatic syringe into a
cubital vein at a rate of 3.5 to 4.0 mL/s. The image processing and
3-dimensional reconstruction were carried out at a computer sta-
tion MagicView 1000 (Siemens Healthcare Services, Oldbury,
Bracknell, United Kingdom). The analysis of 244 vein and 92
arterial grafts was performed by 2 radiologists in a blinded manner.
Also 31 patients were subjected to selective coronary and shunt
angiography by the Judkins technique and a standard protocol used
to define occlusions of vein graft proximal and distal anastomoses.
Thus, both EBCT and coronary angiography were performed in 31
patients, with a total of 67 vein and 31 arterial grafts visualized.
Occlusions of 54 vein and 3 arterial grafts were revealed by EBCT.
These results were all confirmed by angiographic procedure. Thus,
sensitivity and specificity of EBCT for graft occlusions in this
sample was 100%.
The study was conducted in accordance to the Declaration of
Helsinki and approved by the local ethics committee. All patients
gave written informed consent.
Statistical analysis was performed with the MedCalc program,
version 5.00.020 (developed by Mathias Tschopp). In univariate
analysis, continuous variables were compared by 2-tailed t tests;
the Mann-Whitney test was used for variables with non-Gaussian
distribution. Discontinuous variables were compared by the 2 and
Fisher exact tests. Multivariate analysis was done by stepwise
logistic regression to obtain predictive power of risk factors in the
development of vein graft occlusions. Receiver operating charac-
teristic (ROC) curve analysis was used to obtain threshold Lp(a)
for graft occlusions. Data for discontinuous variables are presented
as n (%) and for continuous ones as mean SD or as median (95%
confidence interval) for Lp(a).
Results
Of 102 patients studied, 47 (46%) had arterial hypertension,
62 (61%) had a family history of CHD, and 75 (74%) were
previous or current smokers. Elevated Lp(a) ( 30 mg/dL)
was determined in 39 (38%) patients. Lipid levels of pa-
tients and healthy controls are presented in Table 1. Preop-
eratively, all patients had severe angina pectoris with 2
(11%) or 3 (89%) diseased coronary vessels and 56 (55%)
TABLE 1. Baseline lipids of patients and healthy men
Variable Patients Controls
Lp(a) median (95% CI; mg/dL) 16 (13-24) 8 (4-13)*
Lp(a)  30 mg/dL [n (%)] 39 (38%) 14 (18.4%)*
Total cholesterol (mmol/L) 6.4 1.5 5.7 1.0*
HDL-C (mmol/L) 1.0 0.5 1.4 0.2*
LDL-C (mmol/L) 4.3 1.4 3.7 0.9*
TG (mmol/L) 1.9 1.4 1.9 0.9
HDL-C, High-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; Lp(a), lipoprotein(a); TG, triglycerides; TC, total cholesterol.
*P  .01.
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of them already survived myocardial infarction. The mean
number of distal anastomoses was 3.7  1.0.
We performed bicycle ergometry in 100 patients. Of 33
patients with positive exercise test results, 32 had the symp-
toms of angina pectoris (classes I-IV according to the Ca-
nadian Cardiovascular Society) and 1 patient had silent
ischemia. Atypical angina was present in 68 patients. Of
208 single vein grafts examined, 76 (36.5%) were occluded;
of 19 Y-mode grafts examined, 8 (42%) were occluded; and
of 17 sequential grafts examined, 8 (47%) were occluded.
Occlusion of 1 or more vein grafts was demonstrated in 66
of 102 patients in our study. Patients were then evaluated
according to graft status: 66 (65%) with occlusions and 36
(35%) without occlusions. Of 66 patients with occluded
grafts, half had positive exercise test results. The mean
number of occluded grafts in this subgroup was higher than
in the other half with negative test results: 2.1  1.1 versus
1.4  0.7, t  3.084, 64 d.f., P  .003. No significant
differences were found between the groups with or without
occlusions concerning age, smoking, family history of
CHD, previous myocardial infarction, or hypertension (Ta-
ble 2). More patients with nonoccluded grafts were taking
statins postoperatively: 15 of 36 (42%) versus 12 of 66
(18%) with occluded grafts (P  .05). Concentrations of
serum total cholesterol, triglycerides, HDL-C, LDL-C, and
apoB did not differ between the groups significantly, while
Lp(a) level was higher in patients with occluded grafts.
Currently, the normal range of Lp(a) concentration is
considered to be less than 30 mg/dL. The number of patients
with occluded grafts was significantly higher if the Lp(a)
level was more than 30 mg/dL: 32 of 39 (82%) compared
with 34 of 63 (54%) if Lp(a)  30 mg/dL, P  .005. ROC
curve analysis revealed an Lp(a) threshold level of 28
mg/dL (sensitivity 49%, specificity 81%, positive predictive
value 82%, negative predictive value for  1 occluded graft
46%).
Arterial graft occlusions were detected less frequently
than vein graft occlusions: only 5 of 92 (5.4%) were oc-
cluded during the first year after operation. There were no
differences in classic risk factors and lipid values between
patients with patent and occluded arterial grafts.
Twenty-seven patients received hypolipidemic therapy
with statins after operation. We compared them with 68
patients without any hypolipidemic treatment (7 patients
had taken fibrates or niacin and were not considered in the
analysis). Total cholesterol and LDL-C concentrations were
significantly lower in the first group, whereas other lipid
values did not differ (Table 3). There were more patients
with patent vein grafts among those receiving statins: 15
(55%) versus 21 (28%), P  .02. Of 39 patients with
elevated Lp(a), 10 received statins after the operation. They
had a significantly lower frequency of vein graft occlusion
than the remaining 29 patients: 5 (50%) versus 26 (90%), P
 .05.
In univariate rank sum correlation analysis, Lp(a) (r 
0.230, P  .02), statin therapy (r  0.197, P  .048), and
HDL-C (r  0.193, P  .07) were related to vein graft
occlusions. In a multivariate stepwise logistic regression
model, the only predictors of vein graft occlusions were
Lp(a) level (P  .04) and statin therapy (P  .02).
Discussion
Our study demonstrated the association between Lp(a) level
and vein graft occlusions within the first year after CABG.
Two other retrospective studies9,10 also revealed the relation
of Lp(a) with vein graft lesions, but within several years
after operation when there is a natural course of atheroscle-
rosis of both native coronary arteries and grafts. In a pro-
spective 5-year trial of 176 unselected patients with CABG,
high Lp(a) concentration tended to be associated with ob-
structive changes in vein grafts, whereas mean levels of
serum lipids and lipoproteins, other traditional risk factors
for atherosclerosis, and subcutaneous fatty acid composition
were similar in patients with and without graft occlusion.17
Other prospective trials did not reveal an association of
Lp(a) level with clinical and angiographic outcome 5 years
after CABG.12,18
Our main finding is the demonstration of the relationship
of Lp(a) excess with vein graft occlusions in the first months
after operation when the processes of thrombosis and inti-
mal hyperplasia are prevailing.3 This could be explained by
prothrombotic properties of the Lp(a) particle.6 In vitro
studies have shown that Lp(a) stimulates smooth muscle







Patients (n) 36 66
Age (y) 51 9 53 9
Time after CABG (mo) 5.0 2.9 5.8 3.0
Current smokers 10 (26%) 20 (30%)
Previous myocardial infarction 18 (46%) 38 (57%)
Family history of CHD 21 (54%) 41 (61%)
Hypertension 16 (41%) 31 (46%)
Treatment with statins after CABG 15 (42%) 12 (18%)*
Lp(a) (mg/dL median [95% CI]) 12 [6-24] 24 [17-42]†
Total cholesterol (mmol/L) 6.2 1.3 6.5 1.6
Triglycerides (mmol/L) 1.9 1.8 1.9 1.2
LDL-C (mmol/L) 4.4 1.2 4.6 1.5
LDL-Cc (mmol/L) 4.3 1.2 4.3 1.5
HDL-C (mmol/L) 1.1 1.5 1.0 0.4
Apolipoprotein B (mg/dL) 138 56 138 54
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cell proliferation, may compete for fibrin binding, interacts
with cell plasminogen receptor, and accumulates in throm-
bi.19,20 Therefore, Lp(a) may interfere with fibrinolysis and
support a prothrombotic state. However, a prospective study
of 610 patients undergoing CABG did not find an effect of
Lp(a) level on graft patency at 1 year after CABG.11 Shunt
angiography was performed in 95% of patients at a mean
12.1  1.5 months after surgery. One or more occlusions of
vein graft were revealed in almost half of the patients. The
explanation of the conflict between this and our studies
could lie in differences of patient cohorts; the first one was
unselected and consisted of both men (87%) and women,
whereas our patients were only symptomatic middle-aged
men. Thus, possible reasons for this disagreement could be
the difference in age, sex, and the combination of risk
factors in studied groups. The high rate of graft occlusion in
our study is explained by the inclusion of patients with
symptoms of typical or atypical angina, though two thirds of
them did not have signs of ischemia on ECG. Probably,
stress-echocardiography could help to obtain ischemic signs
in this subgroup, but this method was not included in the
study protocol.
Some studies examined the role of hemostatic factors in
prognosis after CABG. In one of these studies, angiography
performed 10 days postoperatively showed graft occlusion
in 23% of 82 patients. Patients with graft occlusion had
significantly (P  .001) higher preoperative plasminogen
activator inhibitor activity than patients without occlusion.21
These results suggest that increased plasminogen activator
inhibitor activity might have a positive predictive value for
early thrombosis in patients undergoing CABG. Preopera-
tive and postoperative determinations (performed on the
first, third, and sixth postoperative days) of hemostatic
factors were performed in 100 men who had undergone
elective CABG for stable angina pectoris.22 Occlusion of
one or more vein grafts within 3 months of surgery occurred
in 23 of them. The percentage increase in plasma plasmin-
ogen activator inhibitor-1 activity and fibrinogen levels
within the first postoperative week were significantly (P 
.05) higher in patients who subsequently were found to have
vein graft occlusion.22 We propose that in patients with high
Lp(a) level there is an increased risk of thrombotic graft
occlusion due to concurrent inhibition of plasminogen by
Lp(a) particles.
We have determined that therapy with statins is associ-
ated with a lower frequency of graft occlusion even in the
first year after CABG. In the Post-CABG trial, the investi-
gators showed that statin therapy reduced the progression of
vein graft disease, the incidence of vein graft occlusion, and
the need for further revascularization.23 This large study
was started at 1 to 11 years after CABG and angiography
was repeated an average of 4.3 years after baseline. The
hypolipidemic therapy in our study was begun soon after
operation and, though it was not randomized, the use of
statins was associated with significantly better graft func-
tioning in first months after operation. The reduction of
blood thrombogenicity and endothelial dysfunction,24 as
well as anti-inflammatory effect,25,26 may be mechanisms
by which statins improve graft function and patency much
earlier than the retarding of atherosclerosis through hypo-
lipidemic activity.
We found EBCT to have high sensitivity for graft occlu-
sion. Previously, it was shown that evaluation for hemody-
namically relevant stenosis was possible in 84% of cases
(36 of 43 patent grafts) and yielded a sensitivity of 100% (5
of 5 high-grade stenoses correctly detected) and a specificity
of 97%.13 We performed a substudy to compare EBCT and
coronary angiography and obtained comparable accuracy in
the revelation of graft occlusion. Therefore, we believe that
EBCT should be used more widely to assess the condition
of coronary grafts.
In conclusion, we found a significant association be-
tween elevated Lp(a) level and vein graft occlusion in
middle-aged men in their first postoperative year. Patients
not receiving statins and with Lp(a) excess had the highest
rate of vein graft occlusion (90%). It would be useful to





(n  27) P
Lp(a) (mg/dL median [95% CI]) 23 [15-33] 18 [10-36] .5
Total cholesterol (mmol/L baseline) 6.6 1.5 7.0 1.3 .2
Total cholesterol (mmol/L at follow-up) 6.6 1.5 5.6 1.4† .01
Triglycerides (mmol/L baseline) 1.8 1.8 2.0 1.8 .6
Triglycerides (mmol/L at follow-up) 2.1 1.6 1.4 1.1* .02
LDL-C (mmol/L) 4.7 1.4 3.9 1.3 .01
LDL-Cc (mmol/L) 4.5 1.6 3.5 1.5 .006
HDL-C (mmol/L) 1.0 0.4 1.1 0.6 .3
Apolipoprotein B (mg/dL) 140 55 131 46 .5
LDL-Cc, LDL-cholesterol corrected for Lp(a)-cholesterol, as was proposed by G. Dahlen.14
*P  .05; †P  .01, versus baseline levels of total cholesterol and triglycerides.
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measure Lp(a) concentration before surgery because pa-
tients with Lp(a) of 30 mg/dL or greater are at higher risk of
subsequent vein graft lesions. Currently, there is no drug
therapy available to lower Lp(a). Specific extracorporeal
Lp(a) removal by Lp(a) apheresis, a procedure first designed
and performed by our group, may retard progression of
atherosclerosis in patients with selective Lp(a) eleva-
tion.27,28 Taking into consideration the data that cardiovas-
cular risk associated with high Lp(a) level is markedly
enhanced when LDL-C is also elevated,29 soon after CABG
all patients with both higher and normal Lp(a) levels in
association with elevated LDL should receive aggressive
hypolipidemic therapy, with the aim of avoiding fast pro-
gression of atherosclerosis in the bypasses. There is a need
for future work in the investigation of the pathophysiologic
role of Lp(a) in atherothrombosis and, furthermore, large
prospective clinical trials could provide clarity as to the use
of measuring Lp(a) level.
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